natgillin/translations-raw huggingface dataset:
It must not be used in patients with severe liver or kidney problems, sleep apnoea syndrome (frequent interruption of breathing during sleep), myasthenia gravis (a disease causing muscle weakness) or severe respiratory insufficiency (breathing disorders), or in patients under 18 years of age.
Ne sme se uporabljati pri bolnikih s hudimi obolenji jeter ali ledvic, bolnikih s sindromom apneje v spanju (pogoste prekinitve dihanja v spanju), miastenijo gravis (boleznijo, ki povzroča šibkost mišic), bolnikih s hudimi težavami z dihanjem ali pri bolnikih, mlajših od 18 let.
The most common side effects with Sonata (seen in between 1 and 10 patients in 100) are amnesia (memory problems), paraesthesia (unusual sensations like pins and needles), somnolence (sleepiness) and dysmenorrhoea (painful menstruation).
Najpogostejši neželeni učinki zdravila Sonata (opaženi pri 1 do 10 bolnikih izmed 100) so amnezija (motnja spomina), parestezija (nenormalni občutki zbadanja), somnolenca (zaspanost) in dismenoreja (boleča menstruacija).
The powder in Sonata capsules is coloured with an intense dark blue dye, to prevent it being given to someone without their knowledge.
Prašek v kapsulah Sonata je obarvan z intenzivnim temnomodrim barvilom, kar preprečuje, da bi posamezna oseba zdravilo prejela brez svoje vednosti.
In the brain, GABA is involved in bringing about sleep.
GABA v možganih sodeluje pri tem, da človek zaspi.
Five of these studies were comparative: Sonata was compared with placebo (a dummy treatment) or with zolpidem or triazolam (other medicines used in insomnia).
Pet študij je bilo primerjalnih: zdravilo Sonata so primerjali s placebom (zdravilom brez zdravilne učinkovine) ali zolpidemom ali triazolamom (drugima zdraviloma za zdravljenje nespečnosti).
What is the risk associated with Sonata?
Kakšna tveganja so povezana z zdravilom Sonata?
Sonata is a medicine that contains the active substance zaleplon.
Sonata je zdravilo, ki vsebuje zdravilno učinkovino zaleplon.
Sonata is used for the treatment of adults with insomnia who have difficulty falling asleep.
Zdravilo Sonata se uporablja za zdravljenje odraslih z nespečnostjo, ki težko zaspijo.
The active substance in Sonata, zaleplon, belongs to a group of medicines that are related to the benzodiazepines.
Zdravilna učinkovina v zdravilu Sonata, zaleplon, spada v skupino zdravil, ki so podobne benzodiazepinom.
For the full list of all side effects reported with Sonata, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Sonata, glejte navodilo za uporabo.
Sonata should not be used in people who may be hypersensitive (allergic) to zaleplon or any of the other ingredients.
Zdravila Sonata ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) zaleplon ali katero koli drugo sestavino zdravila.
The Committee for Medicinal Products for Human Use (CHMP) decided that Sonata's benefits are greater than its risks for the treatment of patients with insomnia who have difficulty falling asleep, when the disorder is severe, disabling or subjecting the individual to extreme distress.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Sonata pri zdravljenju hude nespečnosti, ki težko zaspijo, kadar je motnja huda, ki osebo onesposobi ali ji povzroča izjemno neugodje, večje od z njim povezanih tveganj.
Sonata 10 mg was more effective than placebo in decreasing the time taken to fall asleep and increasing time spent asleep during the first half of the night.
Zdravilo Sonata v odmerku 10 mg je bilo učinkovitejše od placeba pri skrajševanju časa, potrebnega, da je bolnik zaspal, in pri podaljševanju trajanja spanca v prvi polovici noči.
Why has Sonata been approved?
Zakaj je bilo zdravilo Sonata odobreno?
Sonata must not be taken by children or by patients who have severe liver or kidney problems.
Zdravila Sonata ne smejo jemati otroci ali bolniki s hudim obolenjem jeter ali ledvic.
Sonata is taken immediately before going to bed, or after the patient has gone to bed and is having difficulty falling asleep.
Zdravilo Sonata bolnik vzame tik preden gre v posteljo ali potem, ko je že v postelji in ne more zaspati.
The full EPAR for Sonata is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Sonata je na voljo tukaj.
The time taken to fall asleep was reduced in adults taking Sonata 10 mg, and the effects were maintained for up to four weeks.
Pri odraslih, ki so vzeli 10 mg zdravila Sonata, se je skrajšal čas, potreben, da so zaspali, učinki pa so trajali do štiri tedne.
What is Sonata used for?
Za kaj se zdravilo Sonata uporablja?
What is Sonata?
Kaj je zdravilo Sonata?
How has Sonata been studied?
Kako je bilo zdravilo Sonata raziskano?
How does Sonata work?
Kako zdravilo Sonata deluje?
In elderly patients, the time taken to fall asleep was often decreased with Sonata 5 mg and was always decreased with Sonata 10 mg, when they were compared with placebo in the two-week studies.
V primerjavi s placebom je bil v dvotedenskih študijah pri starejših bolnikih, ki so jemali zdravilo Sonata v odmerku 5 mg, čas, potreben, da so zaspali, pogosto krajši, pri jemanju 10-miligramskih odmerkov pa je bil vedno krajši.
How is Sonata used?
Kako se zdravilo Sonata uporablja?
The maximum total daily dose of Sonata is 10 mg.
Največji celotni dnevni odmerek zdravila Sonata je 10 mg. Bolniki ne smejo vzeti drugega odmerka v isti noči.
Sonata also preserved sleep patterns in the studies that measured the time spent in different stages of sleep.
V študijah, v katerih so merili čas trajanja različnih faz spanja, se je izkazalo, da zdravilo Sonata ohrani vzorce spanja.
Adopted at the 5-8 October 2015 PRAC
Sprejeto na seji odbora PRAC med 5. in 8. oktobrom 2015
Anakinra - Thrombocytopenia (EPITT no 18337)
Anakinra - trombocitopenija (EPITT št. 18337)
In clinical studies in RA and CAPS patients, thrombocytopenia has been reported in 1.9% of treated patients compared to 0.3% in the placebo group.
V kliničnih študijah bolnikov z revmatoidnim artritisom (RA) in s kriopirinom povezanim periodičnim sindromom (CAPS) so o trombocitopeniji poročali pri 1,9 % zdravljenih bolnikov v primerjavi z 0,3 % v skupini s placebom.
New product information wording - Extracts from PRAC recommendations on signals EMA/PRAC/661880/2015
Novo besedilo informacij o zdravilu - izvlečki iz priporočil odbora PRAC o signalih EMA/PRAC/680927/2015
Common side effects (may affect up to 1 in 10 people): - Thrombocytopenia (low level of blood platelets).
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): - trombocitopenija (nizko število trombocitov v krvi).
The thrombocytopenias have been mild, i.e. platelet counts have been >75 x109/l.
Trombocitopenija je bila blaga, tj. število trombocitov je bilo večje od 75 x109/l.
During post-marketing use of Kineret, thrombocytopenia has been reported, including occasional case reports indicating severe thrombocytopenia (i.e. platelet counts <10 x109/l).
O trombocitopeniji so poročali tudi pri uporabi zdravila Kineret v obdobju trženja, vključno z občasnimi poročili o primerih hude trombocitopenije (tj. število trombocitov manjše od 10 x109/l).
Summary of Product Characteristics: Section 4.8 - Undesirable effects:
Povzetek glavnih značilnosti zdravila: Poglavje 4.8 - Neželeni učinki: bolezni krvi in limfatičnega sistema Pogostnost „pogosti“: trombocitopenija
EU Number Invented Name
EU številka Izmišljeno ime
Horses Intramuscular Vials (Type I glass) closed with a halogenobutyl rubber stopper and aluminium cap.
Karenca intramuskularno viale (steklo tipa I), zaprte z zamaški iz halogenobutilne gume in zatesnjene z aluminijastimi zaporkami
Horses Intramuscular Pre-filled syringes (Type I glass) with a plunger and cap tip of halogenobutyl rubber
10 steklenih vial intramuskularno napolnjene brizge (steklo tipa I) z batom z nastavkom iz halogenobutila
1 dose 10 pre-filled syringes
10 napolnjenih brizg
1 bag
1 vreča
Immediate Packaging Content Pack size
Vsebina Velikost pakiranja
ml
Jakost
Intravenous use Ethylen-vinyl-acetate cryo bag (EVA)
5-20 x 106 celic/ml disperzija za infundiranje intravenska uporaba zamrzovalna vreča iz etilen-vinil-acetata
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila in imetnikov dovoljenja za promet z zdravilom v državah članicah
Luxembourg NV AstraZeneca SA Egide Van Ophemstraat 110
Luksemburg NV AstraZeneca SA Egide Van Ophemstraat 110
Czech Republic AstraZeneca UK Limited 2 Kingdom Street
Romunija AstraZeneca UK Limited 2 Kingdom Street
25mg +100mg +200mg (Confezione Starter)
25mg +100mg +200mg (začetno pakiranje)
Filmtabletten +100mg Filmtabletten +200mg Filmtabletten
+100mg filmsko obložene tablete
EMA Number
Številka (EU)
The recommended dose is one capsule once a day at the same time each day.
Priporočeni odmerek je ena kapsula enkrat na dan vedno ob istem času.
Patients should not use more than one capsule in a day.
Bolnik ne sme uporabiti več kot ene kapsule na dan.
The Agency also noted that the fact that the medicine is used once a day may help patients to adhere to their treatment.
Poudarila je tudi, da lahko dejstvo, da se zdravilo uporablja enkrat na dan, pripomore k redni uporabi zdravila.
Further information on Seebri Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije za zdravilo Seebri Breezhaler so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
the main measure of effectiveness was improvement in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).
Glavno merilo učinkovitosti v obeh študijah je bilo izboljšanje forsiranega ekspiracijskega volumna (FEV1 - največje količine zraka, ki jo oseba lahko izdihne v eni sekundi) pri bolnikih.
Therefore, the Agency decided that Seebri Breezhaler's benefits are greater than its risks and it can be authorised for use in the EU.
Zato je agencija zaključila, da so koristi zdravila Seebri Breezhaler večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The most common side effects with Seebri Breezhaler (seen in more than 1 patient in 100) are dry mouth, nasopharyngitis (inflammation of the nose and throat), insomnia (difficulty sleeping), muscle and bone pain and gastroenteritis (diarrhoea and vomiting).
Najpogostejši neželeni učinki zdravila Seebri Breezhaler (opaženi pri več kot 1 bolniku od 100) so suha usta, nazofaringitis (vnetje nosu in žrela), nespečnost (težave s spanjem), bolečine v mišicah in kosteh ter gastroenteritis (driska in bruhanje).
To take a dose, the patient places a capsule into the inhaler and breathes in through the mouth the powder from the capsule.
Odmerek se vzame tako, da bolnik namesti kapsulo v inhalator in skozi usta vdihne prašek iz kapsule.
After 12 weeks of treatment, Seebri Breezhaler increased FEV1 by 97 ml more than with placebo in the first study, and by 108 ml more in the second study.
Po 12 tednih zdravljenja je bilo povečanje vrednosti FEV1 pri uporabi zdravila Seebri Breezhaler v prvi študiji za 97 ml večje kot pri uporabi placeba, v drugi pa za 108 ml.
This means that it widens the airways by blocking muscarinic receptors (targets) in muscle cells in the lungs.
To pomeni, da razširi dihalne poti tako, da zavre muskarinske (ciljne) receptorje v celicah pljučnih mišic.
The European Medicines Agency noted that Seebri Breezhaler had a modest but relevant benefit for patients in terms of improving lung function, and also improved the symptoms of COPD.
Evropska agencija za zdravila je menila, da ima zdravilo Seebri Breezhaler zmerno vendar pomembno korist za bolnike v smislu izboljšanja pljučne funkcije in da izboljšuje simptome KOPD.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Seebri Breezhaler have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Seebri Breezhaler upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Seebri Breezhaler are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Seebri Breezhaler, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.
KOPB je bolezen, pri kateri so dihalne poti in zračni mešički v pljučih poškodovani ali zamašeni, zaradi česar je dihanje oteženo.
Seebri Breezhaler capsules, which contain a powder for inhalation, are only used with the Seebri Breezhaler inhaler and must not be swallowed.
Kapsule zdravila Seebri Breezhaler, ki vsebujejo prašek za inhaliranje, je treba uporabljati izključno z inhalatorjem za zdravilo Seebri Breezhaler in se jih ne sme pogoltniti.
Seebri Breezhaler was found to be more effective than placebo (a dummy treatment) at relieving symptoms of COPD in two main studies involving a total of 1,888 patients with COPD.
Zdravilo Seebri Breezhaler je bilo učinkovitejše od placeba (zdravila brez zdravilne učinkovine) pri lajšanju simptomov KOPD v dveh glavnih študijah, v katerih je sodelovalo skupno 1 888 bolnikov s
Seebri Breezhaler is used for maintenance (regular) treatment.
Zdravilo Seebri Breezhaler se uporablja za vzdrževalno (redno) zdravljenje.
As for all medicines, data on the use of Seebri Breezhaler are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Seebri Breezhaler stalno spremljajo.
For more information about treatment with Seebri Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Seebri Breezhaler preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Seebri Breezhaler and why it is authorised in the EU
Pregled zdravila Seebri Breezhaler in zakaj je odobreno v EU
Seebri Breezhaler received a marketing authorisation valid throughout the EU for Seebri Breezhaler on 28 September 2012.
Za zdravilo Seebri Breezhaler je bilo 28. septembra 2012 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
In addition, there were no major safety concerns with Seebri Breezhaler, with side effects similar to other muscarinic receptor antagonist medicines.
Poleg tega ni ugotovila nobenih zadržkov glede varnosti zdravila Seebri Breezhaler, njegovi neželeni učinki pa so podobni tistim, ki so značilni za ostale antagoniste muskarinskih receptorjev.
What measures are being taken to ensure the safe use of Seebri Breezhaler?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Seebri Breezhaler?
Why is Seebri Breezhaler authorised in the EU?
Zakaj je bilo zdravilo Seebri Breezhaler odobreno v EU?
Other information about Seebri Breezhaler
Druge informacije o zdravilu Seebri Breezhaler
The active substance in Seebri Breezhaler, glycopyrronium bromide, is a muscarinic receptor antagonist.
Zdravilna učinkovina v zdravilu Seebri Breezhaler, glikopironijev bromid, je antagonist muskarinskih receptorjev.
Seebri Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Zdravilo Seebri Breezhaler se uporablja za lajšanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
What is Seebri Breezhaler and what is it used for?
Kaj je zdravilo Seebri Breezhaler in za kaj se uporablja?
For more information about using Seebri Breezhaler, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Seebri Breezhaler glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What benefits of Seebri Breezhaler have been shown in studies?
Kakšne koristi je zdravilo Seebri Breezhaler izkazalo v študijah?
For the full list of all side effects and restrictions with Seebri Breezhaler, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Seebri Breezhaler glejte navodilo za uporabo.
What are the risks associated with Seebri Breezhaler?
Kakšna tveganja so povezana z zdravilom Seebri Breezhaler?
Muscarinic receptors control the contraction of muscles and when glycopyrronium bromide is inhaled, it relaxes the muscles of the airways.
Muskarinski receptorji nadzirajo krčenje mišic in ob vdihu glikopironijevega bromida se mišice dihalnih poti sprostijo, kar pripomore, da ostanejo dihalne poti odprte, in omogoča bolniku, da lažje diha.
How is Seebri Breezhaler used?
Kako se zdravilo Seebri Breezhaler uporablja?
How does Seebri Breezhaler work?
Kako zdravilo Seebri Breezhaler deluje?
Seebri Breezhaler contains the active substance glycopyrronium bromide.
Vsebuje zdravilno učinkovino glikopironijev bromid.
In both studies,
KOPD.
Memantine LEK should be given once a day at the same time every day.
Zdravilo Memantine LEK se daje enkrat dnevno, vsak dan ob istem času.
To prevent side effects, the dose of Memantine LEK is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine LEK v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat dnevno.
The full EPAR for Memantine LEK can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Memantine LEK je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Memantine LEK?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Memantine LEK?
Memantine LEK is a medicine used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Memantine LEK je zdravilo, ki se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo, vrsto demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
This means that Memantine LEK is similar to a ‘reference medicine' already authorised in the European Union (EU) called Ebixa.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Ebixa.
This is a summary of the European public assessment report (EPAR) for Memantine LEK.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Memantine LEK.
The European Commission granted a marketing authorisation valid throughout the European Union for Memantine LEK on 22 April 2013.
Evropska komisija je dovoljenje za promet z zdravilom Memantine LEK, veljavno po vsej Evropski uniji, odobrila dne 22. aprila 2013.
What are the benefits and risks of Memantine LEK?
Kakšne so koristi in tveganja, povezani z zdravilom Memantine LEK?
The Committee recommended that Memantine LEK be approved for use in the EU.
Priporočil je, da se zdravilo Memantine LEK odobri za uporabo v EU.
Memantine LEK is available as 10 mg and 20 mg tablets and can only be obtained with a prescription.
Zdravilo Memantine LEK je na voljo v obliki 10- in 20-miligramskih tablet in se izdaja le na recept.
Because Memantine LEK is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Memantine LEK generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine LEK by the patient.
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Memantine LEK.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine LEK has been shown to have comparable quality and to be bioequivalent to Axura.
Odbor za zdravila za uporabo v humani medicini (CHMP), ki deluje pri agenciji, je zaključil, da je bilo v s skladu z zahtevami EU dokazano, da ima zdravilo Memantine LEK primerljivo raven kakovosti kot zdravilo Axura ter da mu je biološko enakovredno.
What is Memantine LEK and what is it used for?
Kaj je zdravilo Memantine LEK in za kaj se uporablja?
For more information about treatment with Memantine LEK, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Memantine LEK preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Memantine LEK is a ‘generic medicine'.
Zdravilo Memantine LEK je „generično“ zdravilo.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine LEK should be reassessed on a regular basis.
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom
Safety information has been included in the summary of product characteristics and the package leaflet for Memantine LEK, including the appropriate precautions to be followed by healthcare professionals and patients.
V povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Memantine LEK so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Memantine LEK, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Memantine LEK naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Because Memantine LEK is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Axura.
Ker je zdravilo Memantine LEK generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Axura.
Other information about Memantine LEK
Druge informacije o zdravilu Memantine LEK
It is not intended to provide practical advice on how to use Memantine LEK.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Therefore, the CHMP's view was that, as for Axura, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Axura, odtehtajo znana tveganja.
Why is Memantine LEK approved?
Zakaj je bilo zdravilo Memantine LEK odobreno?
The active substance in Memantine LEK, memantine, is an antidementia medicine.
Zdravilna učinkovina zdravila Memantine LEK, memantin, je zdravilo za zdravljenje demence.
How has Memantine LEK been studied?
Kako je bilo zdravilo Memantine LEK raziskano?
How is Memantine LEK used?
Kako se zdravilo Memantine LEK uporablja?
How does Memantine LEK work?
Kako zdravilo Memantine LEK deluje?
1 bottle + 1 adapter + 1 oral applicator
1 plastenka + 1 nastavek za plastenko + 1 aplikator za peroralno odmerjanje
Oral solution bottle (HDPE) 230 ml
Peroralna uporaba Plastenka (HDPE) 230 ml
(Invented) name Strength Pharmaceutical Form
(Izmišljeno) ime
Content (concentration) Package size
Farmacevtska oblika Pot uporabe Stična ovojnina Vsebina (koncentracija)